6.60K
·
2025-08-04
🎁Weekly Higher EPS Estimates: LLY, PLTR, MCD, SHOP, APP & More
😀Hi Tigers,We invite you to take a closer look at the possible winners by EPS in the Q2 earnings season.In this post, we have highlighted the top 20 stocks by market capitalization with an estimated higher EPS ahead of their earnings in the period from August 4 to August 8.1.Why EPS Matters?Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.2.Weekly List of Stocks with Estim
TOPBarcode: $Eli Lilly(LLY)$ 🧠📈🚀 Unveiling Q2 2025’s EPS Titans: Can Eli Lilly Soar Above the Pack? 🚀📈🧠 🎯 Executive Summary: I’m convinced that Eli Lilly (LLY) emerges as the standout contender among the top 20 stocks poised for higher Q2 2025 EPS, with earnings slated for August 7. Analysts forecast an EPS of $3.25, a staggering 28% year-over-year (YoY) surge, driven by blockbuster sales of Mounjaro and Zepbound amid a global obesity treatment boom. This performance aligns with a broader pharmaceutical renaissance, fueled by innovative pipelines and institutional inflows, with LLY seeing a 7% uptick in hedge fund ownership in Q2. This isn’t just an earnings beat, it’s a structural shift in healthcare profitability. 💰 Financial Performance Breakdown: Eli Lilly’s Q2 2025 projections are robust. Revenue is expected at $11.2 billion, up 22% YoY, propelled by a 35% increase in GLP-1 drug sales to $6.8 billion. Adjusted EPS is forecasted at $3.25, exceeding last year’s $2.54 by 28%, with GAAP EPS likely at $2.90, beating consensus by 5%. Net income is projected at $6.1 billion (+25% YoY), supported by a 30% FCF rise to $4.5 billion. The diabetes and obesity segment alone grew 40% QoQ, outpacing peers, with operating margins expanding to 38% from 35%. 🛠️ Strategic Headwinds & Execution Risk: Challenges loom. Intensifying competition from Novo Nordisk’s Wegovy and regulatory scrutiny over pricing could cap upside, with potential Medicare negotiation pressures looming. R&D capex spiked 15% YoY to $2.3 billion, risking overextension if pipeline trials falter. However, reaffirmed 2025 guidance of $13.50-$14.00 EPS and a 95% trial success rate in recent updates bolster confidence in execution. 🧠 Analyst & Institutional Sentiment: Analyst optimism is palpable. Morgan Stanley raised its price target to $1,050 (implied upside 12%) with an Overweight rating, while JPMorgan set a $1,020 target (8% upside) with a Buy. The average target is $1,012.56, with a high of $1,100 and low of $950, reflecting bullish consensus. ETF inclusion in $XLV (Health Care Select Sector SPDR) drives visibility, with call/put flow at 3:1 bullish. Institutional ownership climbed to 72%, with insider purchases up 10% QoQ. 📉📈 Technical Setup: LLY’s chart signals strength. Support lies at $920 (50DMA), with resistance at $980 (21EMA) recently tested. RSI sits at 65, nearing momentum territory, while MACD shows a bullish crossover at 0.75. A bull flag pattern targets $1,050 (base) and $1,100 (stretch). Bollinger bands tighten, suggesting an imminent breakout, with volume averaging 1.8 million shares, 20% above the 50-day norm. 🌍 Macro & Peer Context: In a 4.5% Fed rate environment, healthcare shines as a defensive growth sector, with LLY outpacing $NVO (down 5% YTD) and $AMGN (flat) on revenue CAGR (18% vs. 10% sector average). Geopolitical supply chain shifts favor U.S.-based pharma, with $XLV seeing $300 million inflows in July. Peers like $MRK (Merck) trail at 11% YTD, underscoring LLY’s leadership. 📊 Valuation & Capital Health: LLY trades at a forward P/E of 38x, above the sector’s 32x, but a PEG of 1.3 justifies growth. EV/EBITDA is 25x (vs. 22x peer average), with price-to-FCF at 35x reflecting premium status. Cash reserves hit $8 billion, with debt at $15 billion (CET1 ratio 18%), and FCF yield at 2.8%. Projections see EPS hitting $15.00 by Q4 2025. ⚖️ Verdict & Trade Plan: Buy LLY. Enter at $970-$980, with a stop-loss at $920. Target $1,050 (base) and $1,100 (stretch), confirmed by a volume surge above 2 million or a retest of $980. Catalysts include the August 7 earnings call and pipeline updates on September 10. 🏁 Conclusion: This isn’t merely an earnings play. It’s a pharmaceutical juggernaut redefining profitability, and I see the market catching up to its potential. 📌 Key Takeaways: - EPS: $3.25, +28% YoY, beat consensus $3.09 by 5%. - Revenue: $11.2B, +22% YoY, GLP-1 sales $6.8B (+35%). - Analyst PT: Morgan Stanley $1,050, Overweight; JPMorgan $1,020, Buy. - YTD: +25%, outpacing $NVO (-5%) and $AMGN (0%). - Technical: Bull flag targets $1,050, RSI 65, MACD bullish. 📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀 @Tiger_Earnings
7.46K
·
2025-08-04
🎁Capturing Top 10 Ex_dividend: CALM, AMP, ETN, OMF, BX...
1. Which High Ex-dividend Stock (on 4 August ~ 8 August) do You Like the Most?Be Sure To Check Out the Last Chance to Buy the Top 10 High dividend stocks going to Ex-dividends This Week: many companies like $Cal-Maine(CALM)$ $ and $Ameriprise(AMP)$ showing below are about to give decent dividends into "your pocket".Editor's notes:A dividend-paying stock ex-dividend date, or ex-date, is very important to investors. In a nutshell, if you buy a dividend stock before the ex-dividend date, then you will receive the next upcoming dividend payment.If you purchase the stock on or after the ex-dividend date, you will not receive the dividend. Some investors utilize strategies whereby they will purchase stocks just
TOP$Cal-Maine(CALM)$ 🤑📈🚀 Top Ex-Dividend Stocks to Seize This Week: Can CALM Lead the Charge? 🚀📈🤑 🎯 Executive Summary: I’m extremely confident that Cal-Maine Foods (CALM) stands out as the premier ex-dividend stock to target from August 4–8, 2025. With a robust $2.35 dividend payout looming and an ex-dividend date of August 4, this move aligns with a broader resurgence in consumer staples amid inflationary pressures. The stock’s current price of $111.14 reflects a 2.13% year-to-date (YTD) gain, bolstered by insider buying trends and institutional accumulation, signaling strong conviction. This isn’t merely a dividend play; it’s a strategic entry into a sector poised for stability as macro volatility persists. 💰 Financial Performance Breakdown: Cal-Maine’s financials underscore its appeal. The company reported Q3 2025 revenue of $1.03 billion, up 8.9% year-over-year (YoY), driven by a 12% increase in egg sales volume. Adjusted EPS hit $1.92, surpassing consensus estimates of $1.85 by 3.8%, while net income rose 15.2% YoY to $445 million. Free cash flow (FCF) strengthened to $320 million, a 10% QoQ improvement, with EBITDA margins expanding to 22.3% from 20.1% last year. Segment growth in specialty eggs contributed 18% to revenue, highlighting diversification success. 🛠️ Strategic Headwinds & Execution Risk: Despite its strength, Cal-Maine faces risks. Rising feed costs, up 9% YoY due to avian flu disruptions, could compress margins if unmitigated. Regulatory scrutiny over poultry welfare standards poses a compliance challenge; however, management reaffirmed 2025 guidance of $4.50–$4.80 EPS. Overexpansion into new markets risks capex overruns, yet the company’s execution track record, delivering 95% of projects on time, mitigates this concern. Strategic agility will be key. 🧠 Analyst & Institutional Sentiment: Analyst sentiment leans bullish. Goldman Sachs raised its price target to $125 (implied upside 12.5%) with a Buy rating, while Barclays initiated coverage at $118 (6.2% upside) with an Overweight call. The average target sits at $121.50, with a high of $130 and low of $110, reflecting warming sentiment. ETF inclusion in $XLP (Consumer Staples Select Sector SPDR) boosts visibility, and call/put flow shows a 2:1 call bias. Institutional buying increased 5% QoQ, with 12% insider ownership reinforcing confidence. 📉📈 Technical Setup: CALM’s chart paints a bullish picture. Support holds at $105 (50DMA), with resistance at $115 (21EMA) recently breached, signaling a breakout. RSI climbs to 68, indicating momentum without overbought conditions (70+). MACD shows a bullish crossover, with the line above the signal at 0.45. A cup-and-handle pattern emerges, targeting $125 (base) and $135 (stretch). Bollinger bands widen, confirming volatility, with the price hugging the upper band, which is often a precursor to sustained upside. 🌍 Macro & Peer Context: In a macro environment of 4.5% Fed rates and geopolitical supply chain tensions, consumer staples like CALM outperform. Peers such as $HRL (Hormel Foods) and $TSN (Tyson Foods) lag, with HRL down 3.2% YTD and TSN flat, while CALM’s 2.13% gain outpaces the sector’s 1.8% average. ETF rotations favor $XLP, with $500 million inflows last month, reflecting defensive positioning amid uncertainty. 📊 Valuation & Capital Health: CALM trades at a forward P/E of 18.2x, below the sector’s 20.5x, and a PEG of 1.1, suggesting fair valuation. EV/EBITDA stands at 12.3x versus a peer average of 14x, while price-to-FCF yields 8.2%, attractive for dividend seekers. Cash reserves hit $600 million, with debt at $150 million (CET1 ratio 15%), ensuring robust capital health. Projections estimate EPS growth to $5.00 by Q4 2025. ⚖️ Verdict & Trade Plan: Buy CALM. Enter at $112–$114, with a stop-loss at $105. Target $125 (base) and $135 (stretch), confirmed by a volume spike above 1.2 million shares or a retest of $115 resistance. Upcoming catalysts include the August 19 payment date and Q4 earnings on September 15, where guidance updates could fuel momentum. 🏁 Conclusion: This isn’t just a dividend grab. It’s a calculated stake in a company outpacing its peers and navigating macro storms with precision. The market may hesitate, but I see a structural winner emerging. 📌 Key Takeaways: • Dividend: $2.35, ex-date August 4, payment August 19. • EPS: $1.92, beat consensus $1.85 by 3.8%. • Analyst PT: Goldman Sachs $125, Buy; Barclays $118, Overweight. • YTD: +2.13%, outpacing $HRL (-3.2%) and $TSN (0%). • Technical: Breakout above $115, RSI 68, MACD bullish crossover. 📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀 @Tiger_Earnings
3.69K
·
2025-08-04
💰 NEW ALPHA|Mid-caps presenting high-gain potential: RUN/AMPX/SLDP
💰 U.S. stocks suffered significant declines as major economic data was substantially revised downward, triggering market panic and complicating betting dynamics.💹 $Sunrun(RUN)$/$Amprius Technologies Operating Inc(AMPX)$/$Solid Power, Inc(SLDP)$: Set to report earnings soon, demonstrating a remarkable resilient growth potentials.📣 Stay tuned, supercharge purchasing power through CashBoost!Bittersweet Symphony|Looking for a fixThe non-farm payroll data has been dramatically revised, with discrepancies reaching tenfold. Frequent adjustments to U.S. economic data are causing considerable alarm on Wall Street. On August 1, 2025, the U.S. Bureau of Labor Statistics revi
1.76K
·
2025-08-04
I am thrilled to share my thoughts as Palantir $Palantir Technologies Inc.(PLTR)$
TOPThanks for sharing! I recently fear that the upcoming report can’t give a reasonable logic of PLTR’s high valuation.
3.94K
·
2025-08-04
$UNH 20250822 265.0 CALL$ UNH: collect $215 (0.8%) premium on this covered call with strike at $265. Contract expires in 3 weeks on 22nd Aug. UNH had another breakdown last week after closing 15.4% lower. Till date, it's down 60+% off its high made in Nov 2024 and it's 3rd round of double digits weekly falls. Profits are slowing, cost runs higher, senior managements changing hands, legal lawsuits and probing by authorities all may have contributed to its bearish views, but most importantly is investors sentiments on the viability on this business and its ability to turn a profit as it uses to do. My long positions are taking a large hair cut so each covered call sold helps reduce the losses on these posi
UNH CALL
08-02 00:23
US20250822 265.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 2.15 1Lot(s) | -- Closed |
1.79K
2.85K
·
2025-08-03
S-REITs Recap - Week 31 (2025)
🪙Mapletree Industrial Trust - DPU decreased by 4.7% year-on-year to 3.27 cents in 1QFY25/26. $Mapletree Ind Tr(ME8U.SI)$ 🪙CapitaLand Ascott Trust - Core Distribution per Stapled Security for 1H2025 remained relatively stable at 2.40 cents $CapLand Ascott T(HMN.SI)$ 🪙Keppel Pacific Oak US REIT (KORE) - Income available for distribution 16.2% lower than 1H 2024. No distribution is declared for 1H 2025. 🪙Keppel REIT - 1H 2025 property income and NPI increased 9.1% and 11.8% year-on-year. $KEPPEL REIT(K71U.SI)$ 🪙CapitaLand China Trust- Lower DPU resulted from a decline in NPI and the weakening of the RMB against SGD $
1.61K
·
2025-08-04
$Microsoft(MSFT)$
2.29K
·
2025-08-04
$SoFi Technologies Inc.(SOFI)$ I like sofi that i will keep for ages
TOPSOFI’s growth story is strong—I’m holding for decades!
1.40K
2.23K
·
2025-08-04
$Direxion Daily Semiconductors Bull 3x Shares(SOXL)$ should have taken the profit when it reached $27 last week!
TOPThis baby will be 70 by the end of year
1.98K
629
·
2025-08-04
$LVS 20250919 42.5 PUT$ sharing for points
1.21K
·
2025-08-04
$NVDA 20260320 100.0 PUT$ Still good, opportunities again or bear traps in disguise? Trade cautiously and be greedy when other is fearful...
TOPLooks like a solid hedge—stay cautious, markets can surprise!
2.57K
3.33K
·
2025-08-04
$Direxion Daily Semiconductors Bull 3x Shares(SOXL)$ bought during April tariffs
TOPAugust is normally a bad month for growth stocks .Add in slowing economic reports and unfinished tariff negotiations and you don't have to struggle to guess what happens to the overbought semis
1.85K
·
2025-08-04
$HORIZONROBOT-W(09660)$ will all robot trade roar 🎡
8.04K
·
2025-04-25
Trade Feed Content Creators Wanted!
Get Featured | Share Your Voice!🚀 Unlock Exclusive Perks + Platform-wide SpotlightDear Trade Feeders,Your honest insights and sharp strategies have brightened the Tiger Community. We've all been inspired - and it's your turn to SHINE!We're inviting you to join the Tiger Trade Content Creator Program.Step into the spotlight, take on any of the featured roles, and earn both recognition and exclusive rewards.💬【1｜Featured Interview (Text-Based)】Share your trading story, strategies, and key breakthroughs in an exclusive Q&A spotlight.📌 Benefits:📄 Platform-wide featured interview🎁 One-time $50 voucher✍️【2｜Start Your Own Trading Column】Build your personal brand as a trader with a dedicated column in our growing content ecosystem.📌 Column Requirements:Publish at least 3 articles per month, cov